Ambu already operates in the field of single-use pulmonary endoscopy (visualization of the airways) of which there are approximately 5 million procedures annually. With the acquisition of Invendo Medical, Ambu enters the field of gastrointestinal endoscopy (visualization of the stomach and intestines) of which there are approximately 70 million procedures annually. Advanced reusable medical devices are difficult to sterilize and …

The Walden Group is pleased to announce that it represented Attentus Medical Sales, Inc.,a provider of specialized products to compounding, specialty, and infusion pharmacies, to Medical Specialty Distributors, LLC, a leading alternate site patient supply chain solutions provider and a portfolio company of New Mountain Capital.

The Walden Group is pleased to announce that it represented Millennium Surgical Corp. in its sale to Avalign Technologies, Inc.

The Walden Group is pleased to announce that it represented Argentum Medical, LLC, an advanced woundcare company, in its sale of equity to Shore Capital Partners. Argentum’s core platform technology, Silverlon, is a uniquely designed silver-plated nylon matrix that releases potent silver ions into the wound without staining the skin or increasing bioburden. Validated by several clinical studies, Silverlon dressings …

Sweden’s Svenska Cellulosa Aktiebolaget (SCA), $12.3b global hygiene and forest products company, is buying BSN Medical GmbH, a Germany-based manufacturer of woundcare, noninvasive orthopedic and compression therapy products. The deal weights SCA’s business more toward healthcare. BSN has a major share in several attractive medical product markets and provides SCA with a new growth platform with future industry consolidation opportunities. About 85% of SCA’s sales derives from its hygiene business and about 15% from forest products, which it intends to spinoff to shareholders. Earlier,…

Johnson & Johnson (NYSE: JNJ), a $74.3b manufacturer of pharmaceuticals, medical devices and consumer healthcare products, has agreed to buy Abbott Medical Optics Inc, a global ophthalmic surgical and eye care products company and a unit of Abbott Labs. The deal greatly expands J&J’s $7b eye care segment, by adding ophthalmic products across three business segments — cataract surgery, laser refractive surgery, and consumer eye health (multipurpose contact lens and other solutions). Gives J&J the second…

Abbott Laboratories (NYSE:ABT), a $20.4b maker of diagnostics, medical devices, pharmaceuticals and nutritionals, has agreed to buy St. Jude Medical Inc. (NASDAQ:STJ), a major maker of devices for cardiac rhythm management, cardiovascular, and atrial fibrillation. St. Jude Medical’s strong positions in heart failure devices, atrial fibrillation and cardiac rhythm management complement Abbott’s leading positions in coronary intervention and transcatheter mitral repair. With combined annual sales of ~$8.7b,…

Recent volatility in worldwide markets, weakness in China, terrorism, softness in Europe and emerging markets, budget issues, and healthcare reform dislocations are among the dynamics that have clouded the 2016 picture for healthcare M&A. Here, we help clarfty things.

.China.China is moving from a manufacturing and investment orientation to a consumption/consumer-based economy.The economy is still over-regulated and political freedoms are tight.Yet, China is going through a long-term, inexorable transition.The torrid growth rate has slowed to about 6.5% and stock market circuit breakers awkwardly kick in to prevent radical price swings,

…

The Walden Group is pleased to announce that it has advised Halma plc, a UK-based public company, in its acquisition of Visiometrics, S.L., located outside Barcelona, Spain. On Halma’s behalf, The Walden Group identified Visiometrics as a strategic fit, cultivated a relationship with Visiometrics’ principals, advised Halma on the transaction, and assisted in its completion.

Medtronic’s most recent acquistion target was Lazarus Effect, a maker of stroke diagnostic devices. After obtaining European approval, Lazarus Effect is working to get U.S. approval for the ReCover brain blot clot removal device, which works with Medtronic ‘s Solitaire stent that can be deployed in the brain to scoop out vessel-blocking clots that cause acute ischemic stroke. ReCover removes clots from the brain using a “novel nitinol ‘mesh cover’ that folds over a stent retriever device during clot retrieval and ‘candy wraps’ the stent with the clot inside